论文部分内容阅读
我们对从一名越南儿童体内分离出的来自G1P[8]型轮状病毒的减毒候选菌株制成的轮状病毒口服活疫苗做了检测,在29名健康成年人中首次对该疫苗的安全性做了试验。当确定该疫苗安全之后,我们给6～12周龄的160名儿童(分成4组)用了一定剂量后对免疫原性和安全性做了进一步研究,并制定了免疫程序。病毒滴度控制在较低剂量(106.0FFU/剂)时的程序为:免疫两次,间隔时间是两个月(2L组)和免疫三次,间隔一个月(3L组)。
We tested an oral live rotavirus strain of rotavirus made from an attenuated candidate strain of G1P [8] rotavirus isolated from a Vietnamese child in 29 healthy adults for the first time Safety tested. After confirming the safety of the vaccine, we further studied the immunogenicity and safety of 160 children aged 6-12 weeks (divided into 4 groups) at a dose and developed an immunization schedule. The procedure for controlling the virus titer at the lower dose (106.0 FFU / dose) was: immunization twice with intervals of two months (group 2L) and three immunizations with one month interval (group 3L).